Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.55 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 11/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509615 | 0.85 | GAK (0.44) | RETGAK | |
| SCHEMBL12461828 | 0.85 | ACVR2A (0.48) | RET | |
| SCHEMBL12461799 | 0.84 | RET (0.48) | RETGAK | |
| SCHEMBL12461830 | 0.84 | ERN1 (0.47) | RETGAK | |
| SCHEMBL12461821 | 0.83 | RET (0.48) | RET | |
| SCHEMBL12461307 | 0.83 | ERN1 (0.48) | RETGAK | |
| SCHEMBL2288882 | 0.82 | MARK3 (0.49) | MKNK1MKNK2RETCHEK1CHEK2 | |
| SCHEMBL1903502 | 0.82 | KDR (0.50) | RETGAK | |
| SCHEMBL1903169 | 0.82 | MKNK1 (0.48) | MKNK1MKNK2RETPLAU | |
| SCHEMBL12461272 | 0.81 | RET (0.49) | RETGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | claimed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | claimed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | MKNK1 46/4885MKNK2 40/4885MAP3K11 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.